RU2016136504A3 - - Google Patents

Download PDF

Info

Publication number
RU2016136504A3
RU2016136504A3 RU2016136504A RU2016136504A RU2016136504A3 RU 2016136504 A3 RU2016136504 A3 RU 2016136504A3 RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A RU2016136504 A RU 2016136504A RU 2016136504 A3 RU2016136504 A3 RU 2016136504A3
Authority
RU
Russia
Application number
RU2016136504A
Other languages
Russian (ru)
Other versions
RU2016136504A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016136504A publication Critical patent/RU2016136504A/ru
Publication of RU2016136504A3 publication Critical patent/RU2016136504A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016136504A 2014-03-03 2015-03-02 ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ RU2016136504A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947398P 2014-03-03 2014-03-03
US61/947,398 2014-03-03
PCT/US2015/018335 WO2015134399A1 (en) 2014-03-03 2015-03-02 Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
RU2016136504A RU2016136504A (ru) 2018-04-03
RU2016136504A3 true RU2016136504A3 (enExample) 2018-10-25

Family

ID=54055761

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016136504A RU2016136504A (ru) 2014-03-03 2015-03-02 ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ

Country Status (11)

Country Link
US (1) US20170071903A1 (enExample)
EP (1) EP3113775A4 (enExample)
JP (1) JP2017507151A (enExample)
KR (1) KR20160135230A (enExample)
CN (1) CN106029070A (enExample)
AU (1) AU2015225436A1 (enExample)
CA (1) CA2940983A1 (enExample)
IL (1) IL247586A0 (enExample)
RU (1) RU2016136504A (enExample)
SG (1) SG11201607298QA (enExample)
WO (1) WO2015134399A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
HRP20161157T1 (hr) 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposomski pripravak
AU2014299699B2 (en) 2013-06-26 2019-10-10 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
WO2017188350A1 (ja) * 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
JP2022506829A (ja) * 2018-11-09 2022-01-17 ジー1、セラピューティクス、インコーポレイテッド エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
EP2470177B1 (en) * 2009-08-27 2015-07-15 Bionomics Limited Combination therapy for treating proliferative diseases
EP2680839A1 (en) * 2011-03-02 2014-01-08 Morphotek, Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
EP2833915A1 (en) * 2012-04-02 2015-02-11 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies

Also Published As

Publication number Publication date
WO2015134399A1 (en) 2015-09-11
RU2016136504A (ru) 2018-04-03
KR20160135230A (ko) 2016-11-25
EP3113775A1 (en) 2017-01-11
IL247586A0 (en) 2016-11-30
CA2940983A1 (en) 2015-09-11
AU2015225436A1 (en) 2016-09-08
CN106029070A (zh) 2016-10-12
EP3113775A4 (en) 2017-08-23
SG11201607298QA (en) 2016-09-29
JP2017507151A (ja) 2017-03-16
US20170071903A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
BR112016016761A2 (enExample)
BR112016015519A2 (enExample)
BR112016015890A2 (enExample)
BR112016017027A2 (enExample)
BR112016016490A2 (enExample)
BR112016016834A2 (enExample)
BR112016016546A2 (enExample)
BR112016014949A2 (enExample)
BR112016016612A2 (enExample)
BR112016016924A2 (enExample)
BR112016016421A2 (enExample)
BR112016016106A2 (enExample)
BR112016012568A2 (enExample)
BR112016016823A2 (enExample)
BR112016016558A2 (enExample)
AP2017009837A0 (enExample)
BR112016016389A2 (enExample)
BR112016016468A2 (enExample)
BR112016015915A2 (enExample)
BR112016016149A2 (enExample)
BR112016015963A2 (enExample)
BR112016003522A2 (enExample)
BR112016016459A2 (enExample)
BR112016014482A2 (enExample)
BR112016015538A2 (enExample)